Binding of thymoglobulin to natural killer cells leads to cell activation and interferon-γ production

Transplantation

Volumn 87, Issue 4, 2009, Pages 473-481

  Dalle, Jean Hugues ^a   Dardari, R'Kia ^b   Menezes, José ^b   Cordeiro, Paulo ^b   Champagne, Martin A ^b   Duval, Michel ^b  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Antithymocyte globulin; Hematopoietic transplantation; Natural killer cells

Indexed keywords

CD18 ANTIGEN; CD69 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 15; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MONOCLONAL ANTIBODY; NATURAL KILLER CELL RECEPTOR NKG2D; THYMOCYTE ANTIBODY; CHROMIUM; IMMUNOGLOBULIN G;

ANTIGEN BINDING; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BINDING COMPETITION; CELL ACTIVATION; CELL DEATH; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEGRANULATION; DRUG TARGETING; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NORMAL HUMAN; PRIORITY JOURNAL; ADULT; ANIMAL; BIOSYNTHESIS; CYTOLOGY; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; PHYSIOLOGY; PROTEIN BINDING; RABBIT; REFERENCE VALUE;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; CELL DEATH; CHROMIUM RADIOISOTOPES; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; PROTEIN BINDING; RABBITS; REFERENCE VALUES;

EID: 65649111533     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181949c57     Document Type: Article

References (41)

1. Thomas E, Storb R, Clift RA, et al. Bone-marrow transplantation (first of two parts). N Engl J Med 1975; 292: 832.
2. Armitage JO. Bone marrow transplantation. N Engl J Med 1994; 330: 827.
3. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324: 667.
4. Kroger N, Sayer GH, Schwerdtfeger R, et al. Unrelated stem cell transplantation in multiple myeloma after a reduced intensity conditioning with pretransplant anti-thymocyte globulin is highly effective with low transplantation related mortality. Blood 2000; 100: 3911.
5. Zander AR, Kröger N, Schleuning M, et al. ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML). Bone Marrow Transplant 2003; 32: 355.
6. Bonnefoy-Berard N, Revillard JP. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant 1996; 15: 435.
7. Zand MS, Vo T, Huggins J, et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005; 79: 1507.
8. Beiras-Fernandez A, Walther S, Muenzing S, et al. In vitro assessment of dose-dependent platelet activation by polyclonal antithymocyte globulins: A flow-cytometric analysis. Transplantation 2004; 78: 751.
9. Fang L, Fehse B, Engel M, et al. Antithymocyte globulin induces ex vivo and in vivo depletion of myeloid and plasmacytoid dendritic cells. Transplantation 2005; 79: 369.
10. Neudorf S, Jones M. The effects of antithymocyte globulin on natural killer cells. Exp Hematol 1988; 16: 831.
11. Degli-Esposti MA, Smyth MJ. Close encounters of different kinds: Dendritic cells andNKcells take centre stage. Nat Rev Immunol 2005; 5: 112.
12. Lanier LL. Natural killer cell receptor signaling. Curr Opin Immunol 2003; 15: 308.
13. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097.
14. Leung W, Iyengar R, Turner V, et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004; 172: 644.
15. Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003; 102: 814.
16. Davies SM, Ruggieri L, DeFor T, et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Blood 2002; 100: 3825.
17. Guttmann RD, Caudrelier P, Alberici G, et al. Pharmacokinetics, foreign protein immune response, cytokine release, and lymphocyte subsets in patients receiving thymoglobuline and immunosuppression. Transplant Proc 1997; 29: 24S.
18. Genestier L, Fournel S, Flacher M, et al. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood 1998; 91: 2360.
19. Préville X, Nicolas L, Flacher M, et al. A quantitative flow cytometry assay for the preclinical testing and pharmacological monitoring of rabbit antilymphocyte globulins (rATG). J Immunol Methods 2000; 245: 45.
20. Hasbold J, Gett AV, Rush JS, et al. Quantitative analysis of lymphocyte differentiation and proliferation in vitro using carboxyfluorescein diacetate succinimidyl ester. Immunol Cell Biol 1999; 77: 516.
21. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004; 294: 15.
22. Bonnefoy-Berard N, Vincent C, Revillard JP. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 1991; 51: 669.
23. Raefsky EL, Gascon P, Gratwohl A, et al. Biological and immunological characterization of ATG and ALG. Blood 1986; 68: 712.
24. Bourdage JS, Hamlin DM. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation 1995; 59: 1194.
25. Dalle JH, Menezes J, Wagner E, et al. Characterization of cord blood natural killer cells: Implications for transplantation and neonatal infections. Pediatr Res 2005; 57: 649.
26. Bryceson YT, March ME, Barber DF, et al. Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J Exp Med 2005; 202: 1001.
27. Moretta A, Poggi A, Pende D, et al. CD69-mediated pathway of lymphocyte activation: Anti-CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolytic T lymphocytes expressing T cell receptor. J Exp Med 1991; 174: 1393.
28. Pessino A, Sivori S, Bottino C, et al. Molecular cloning of NKp46: A novel memberof the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med 1998; 88: 953.
29. Sivori S, Vitale M, Morelli L, et al. p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J Exp Med 1997; 186: 1129.
30. Leibson PJ. Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity 1997; 6: 655.
31. Michallet MC, Préville X, Flacher M, et al. Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation 2003; 75: 657.
32. Takeda K, Smyth MJ, Cretney E, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002; 195: 171.
33. Langaas V, Shahzidi S, Johnsen JI, et al. Interferon-gamma modulates TRAIL-mediated apoptosis in human colon carcinoma cells. Anticancer Res 2001; 21: 3733.
34. Ruiz-Ruiz C, Lopez-Rivas A. Mitochondria-dependent and-independent mechanisms in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis are both regulated by interferon-gamma in human breast tumour cells. Biochem J 2002; 365:825.
35. Wang SH, Mezosi E, Wolf JM, et al. IFNγ sensitization to TRAIL-induced apoptosis in human thyroid carcinoma cells by upregulating Bak expression. Oncogene 2004; 23: 928.
36. Smyth MJ, Takeda K, Hayakawa Y, et al. Nature's TRAIL-on a path to cancer immunotherapy. Immunity 2003; 18: 1.
37. Bradley M, Zeytun A, Rafi-Janajreh A, et al. Role of spontaneous and interleukin-2-induced natural killer cell activity in the cytotoxicity and rejection of Fas+ and Fas - tumor cells. Blood 1998; 92: 4248.
38. Tsukada N, Kobata T, Aizawa Y, et al. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Blood 1999; 93: 2738.
39. Penack O, Fischer L, Gentilini C, et al. The type of ATG matters - Natural killer cells are influenced differentially by Thymoglobulin, Lymphoglobulin and ATG-Fresenius. Transpl Immunol 2007; 18:85.
40. Nitta T, Yagita H, Sato K, et al. Involvement of CD56 (NKH-1/Leu-19 antigen) as an adhesion molecule in natural killer-target cell interaction. J Exp Med 1989; 170: 1757.
41. Duval M, Pédron B, Rohrlich P, et al. Immune reconstitution after haematopoietic transplantation with two different doses of pre-graft antithymocyte globulin. Bone Marrow Transplant 2002; 30: 421.